NCT00003353 2023-06-22
High-Dose Melphalan Plus Peripheral Stem Cell Transplantation in Treating Patients With Primary Systemic Amyloidosis
Eastern Cooperative Oncology Group
Phase 2 Completed
Clinical Trials
9 trialsNCT00064337 2018-08-09
S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis
SWOG Cancer Research Network
Phase 2 Completed
NCT00681044 2017-04-28
HD Melphalan and SCT in Patients With IGDD or LCDD
Boston Medical Center
Phase 2 Terminated
NCT00790647 2017-02-06
Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis
Boston Medical Center
Phase 2 Completed
NCT00075608 2017-01-27
2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) Amyloidosis
Boston Medical Center
Phase 2 Terminated
NCT00003163 2014-01-06
Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00007995 2013-02-04
Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients Who Have Multiple Myeloma or Primary Systemic Amyloidosis
National Cancer Institute (NCI)
Phase 2 Completed
NCT00089167 2013-01-16
Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic Amyloidosis
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00002810 2010-10-01
High-Dose Melphalan Followed by Peripheral Stem Cell Transplant in Treating Patients With Amyloidosis
Temple University
Phase 2 Completed